{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T07:08:48Z","timestamp":1786864128619,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T00:00:00Z","timestamp":1769299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T00:00:00Z","timestamp":1769299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pressurized intraperitoneal aerosol chemotherapy (PIPAC) offers a localized palliative treatment option for patients with colorectal peritoneal metastases (CPM), often combined with systemic therapy to maximize anti-tumor efficacy. This study on the pharmacokinetics of oxaliplatin-based PIPAC with electrostatic precipitation (ePIPAC-OX) aimed to determine the absolute bioavailability of oxaliplatin in plasma after ePIPAC-OX with reference to systemic therapy and to gain insights for optimizing therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This analysis included patients of the recently published CRC-PIPAC-II study, who received three cycles of oxaliplatin-based systemic therapy and ePIPAC-OX for unresectable CPM. Whole-blood and plasma ultrafiltrate samples were collected at five to six time points after both intravenous oxaliplatin and ePIPAC-OX. Pharmacokinetics were analyzed using population modeling. Absolute bioavailability was calculated as the fraction of the Area under the Curve (AUC0-\u221e)  of the systemic oxaliplatin exposure after intraperitoneal administration over the AUC after intravenous administration, corrected for the dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 18 patients, mostly treated with capecitabine and oxaliplatin (CAPOX) and bevacizumab (15 patients). The median dose-uncorrected AUC of systemic oxaliplatin and ePIPAC-OX in plasma was 165.2 \u03bcg*h\/mL and 57.4 \u03bcg*h\/mL, respectively. The median bioavailability of the total concentration and free fraction of oxaliplatin after ePIPAC-OX were both 48 % (interquartile range [IQR] 42\u201357 %). Dose reduction due to toxicity was required for eight patients (44 %). All the included patients experienced short-term symptoms of acute sensory neuropathy, with eight cases occurring after ePIPAC-OX.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This is the first study to examine the absolute bioavailability of oxaliplatin administered by ePIPAC-OX in humans, using intra-patient data as a control measurement. The systemic bioavailability of oxaliplatin was substantial after ePIPAC-procedures. Therefore, ePIPAC-OX cannot be considered as solely a local treatment. Future research should take this into account for patients treated with both systemic chemotherapy and ePIPAC-OX as bidirectional therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-025-18874-6","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T23:18:28Z","timestamp":1769296708000},"page":"3004-3017","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Absolute Bioavailability of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC): Systemic Pharmacokinetics of the CRC-PIPAC-II Trial"],"prefix":"10.1245","volume":"33","author":[{"given":"Teun B. M.","family":"van den Heuvel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulien","family":"Rauwerdink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Hulshof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent C. J.","family":"van de Vlasakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk Jan A. R.","family":"Moes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pluimakers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen P. B.","family":"Rovers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert-Jan","family":"Creemers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim J. W. A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon W.","family":"Nienhuijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 J.","family":"Wiezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin J.","family":"Lurvink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djamila","family":"Boerma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace H. J. T.","family":"De Hingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"Deenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,25]]},"reference":[{"key":"18874_CR1","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.ejso.2020.11.135","volume":"47","author":"RJ Lurvink","year":"2021","unstructured":"Lurvink RJ, Bakkers C, Rijken A, et al. Increase in the incidence of synchronous and metachronous peritoneal metastases in patients with colorectal cancer: a nationwide study. Eur J Surg Oncol. 2021;47:1026\u201333.","journal-title":"Eur J Surg Oncol."},{"key":"18874_CR2","doi-asserted-by":"publisher","first-page":"9073","DOI":"10.1245\/s10434-021-10190-z","volume":"28","author":"C Bakkers","year":"2021","unstructured":"Bakkers C, Lurvink RJ, Rijken A, et al. Treatment strategies and prognosis of patients with synchronous or metachronous colorectal peritoneal metastases: a population-based study. Ann Surg Oncol. 2021;28:9073\u201383.","journal-title":"Ann Surg Oncol."},{"key":"18874_CR3","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","volume":"17","author":"J Franko","year":"2016","unstructured":"Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17:1709\u201319.","journal-title":"Lancet Oncol."},{"key":"18874_CR4","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1093\/annonc\/mdq762","volume":"22","author":"YL Klaver","year":"2011","unstructured":"Klaver YL, Lemmens VE, Creemers GJ, et al. Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy. Ann Oncol. 2011;22:2250\u20136.","journal-title":"Ann Oncol."},{"key":"18874_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ejso.2012.03.008","volume":"38","author":"YL Klaver","year":"2012","unstructured":"Klaver YL, Simkens LH, Lemmens VE, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38:617\u201323.","journal-title":"Eur J Surg Oncol."},{"key":"18874_CR6","first-page":"1","volume":"62","author":"RL Dedrick","year":"1978","unstructured":"Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1\u201311.","journal-title":"Cancer Treat Rep."},{"key":"18874_CR7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1470-2045(03)01074-X","volume":"4","author":"M Markman","year":"2003","unstructured":"Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol. 2003;4:277\u201383.","journal-title":"Lancet Oncol."},{"key":"18874_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-044811","volume":"11","author":"RJ Lurvink","year":"2021","unstructured":"Lurvink RJ, Rauwerdink P, Rovers KP, et al. First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II). BMJ Open. 2021;11:e044811.","journal-title":"BMJ Open."},{"key":"18874_CR9","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1245\/s10434-020-09558-4","volume":"28","author":"KP Rovers","year":"2021","unstructured":"Rovers KP, Wassenaar ECE, Lurvink RJ, et al. Pressurized intraperitoneal aerosol chemotherapy (oxaliplatin) for unresectable colorectal peritoneal metastases: a multicenter, single-arm, phase II trial (CRC-PIPAC). Ann Surg Oncol. 2021;28:5311\u201326.","journal-title":"Ann Surg Oncol."},{"issue":"Suppl 5","key":"18874_CR10","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1245\/s10434-016-5108-4","volume":"23","author":"T Kakchekeeva","year":"2016","unstructured":"Kakchekeeva T, Demtroder C, Herath NI, et al. In vivo feasibility of electrostatic precipitation as an adjunct to pressurized intraperitoneal aerosol chemotherapy (ePIPAC). Ann Surg Oncol. 2016;23(Suppl 5):592\u20138.","journal-title":"Ann Surg Oncol."},{"key":"18874_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202000655","volume":"9","author":"L Van de Sande","year":"2020","unstructured":"Van de Sande L, Rahimi-Gorji M, Giordano S, et al. Electrostatic intraperitoneal aerosol delivery of nanoparticles: proof of concept and preclinical validation. Adv Healthc Mater. 2020;9:e2000655.","journal-title":"Adv Healthc Mater."},{"key":"18874_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1245\/s10434-020-08743-9","volume":"28","author":"RJ Lurvink","year":"2021","unstructured":"Lurvink RJ, Tajzai R, Rovers KP, et al. Systemic pharmacokinetics of oxaliplatin after intraperitoneal administration by electrostatic pressurized intraperitoneal aerosol chemotherapy (ePIPAC) in patients with unresectable colorectal peritoneal metastases in the CRC-PIPAC trial. Ann Surg Oncol. 2021;28:265\u201372.","journal-title":"Ann Surg Oncol."},{"key":"18874_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.108487","volume":"50","author":"P Rauwerdink","year":"2024","unstructured":"Rauwerdink P, van de Vlasakker VCJ, Wassenaar ECE, et al. First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: a single-arm phase II trial (CRC-PIPAC-II). Eur J Surg Oncol. 2024;50:108487.","journal-title":"Eur J Surg Oncol."},{"key":"18874_CR14","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2217\/pgs.15.70","volume":"16","author":"LM Henricks","year":"2015","unstructured":"Henricks LM, Lunenburg CA, Meulendijks D, et al. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. Pharmacogenomics. 2015;16:1277\u201386.","journal-title":"Pharmacogenomics."},{"key":"18874_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-030408","volume":"9","author":"KP Rovers","year":"2019","unstructured":"Rovers KP, Lurvink RJ, Wassenaar EC, et al. Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, single-arm, phase II study (CRC-PIPAC). BMJ Open. 2019;9:e030408.","journal-title":"BMJ Open."},{"key":"18874_CR16","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s11095-007-9361-x","volume":"24","author":"AC Hooker","year":"2007","unstructured":"Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res. 2007;24:2187\u201397.","journal-title":"Pharm Res."},{"key":"18874_CR17","unstructured":"Price G, Patel DA. Drug Bioavailability. StatPearls. Treasure Island (FL)2025."},{"key":"18874_CR18","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00228-008-0511-9","volume":"64","author":"H Mahteme","year":"2008","unstructured":"Mahteme H, Wallin I, Glimelius B, et al. Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneal perfusion. Eur J Clin Pharmacol. 2008;64:907\u201311.","journal-title":"Eur J Clin Pharmacol."},{"key":"18874_CR19","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1245\/s10434-012-2790-8","volume":"20","author":"JC Leinwand","year":"2013","unstructured":"Leinwand JC, Bates GE, Allendorf JD, et al. Body surface area predicts plasma oxaliplatin and pharmacokinetic advantage in hyperthermic intraoperative intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20:1101\u20134.","journal-title":"Ann Surg Oncol."},{"key":"18874_CR20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.21037\/jgo.2016.01.05","volume":"7","author":"MD Goodman","year":"2016","unstructured":"Goodman MD, McPartland S, Detelich D, Saif MW. Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. J Gastrointest Oncol. 2016;7:45\u201357.","journal-title":"J Gastrointest Oncol."},{"key":"18874_CR21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40487-021-00168-y","volume":"9","author":"J Burgess","year":"2021","unstructured":"Burgess J, Ferdousi M, Gosal D, et al. Chemotherapy-induced peripheral neuropathy: epidemiology, pathomechanisms and treatment. Oncol Ther. 2021;9:385\u2013450.","journal-title":"Oncol Ther."},{"key":"18874_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1515\/pp-2016-0005","volume":"1","author":"M Reymond","year":"2016","unstructured":"Reymond M, Demtroeder C, Solass W, et al. Electrostatic precipitation pressurized intraperitoneal aerosol chemotherapy (ePIPAC): first in-human application. Pleura Peritoneum. 2016;1:109\u201316.","journal-title":"Pleura Peritoneum."},{"key":"18874_CR23","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1016\/j.ejso.2019.06.018","volume":"45","author":"W Willaert","year":"2019","unstructured":"Willaert W, Van de Sande L, Van Daele E, et al. Safety and preliminary efficacy of electrostatic precipitation during pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable carcinomatosis. Eur J Surg Oncol. 2019;45:2302\u20139.","journal-title":"Eur J Surg Oncol."},{"key":"18874_CR24","first-page":"204","volume":"126","author":"D Zemel","year":"1995","unstructured":"Zemel D, Struijk DG, Dinkla C, et al. Effects of intraperitoneal cyclooxygenase inhibition on inflammatory mediators in dialysate and peritoneal membrane characteristics during peritonitis in continuous ambulatory peritoneal dialysis. J Lab Clin Med. 1995;126:204\u201315.","journal-title":"J Lab Clin Med."},{"key":"18874_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1515\/pp-2017-0015","volume":"2","author":"C Eveno","year":"2017","unstructured":"Eveno C, Haidara A, Ali I, et al. Experimental pharmacokinetics evaluation of chemotherapy delivery by PIPAC for colon cancer: first evidence for efficacy. Pleura Peritoneum. 2017;2:103\u20139.","journal-title":"Pleura Peritoneum."},{"key":"18874_CR26","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/jso.21569","volume":"101","author":"S Turcotte","year":"2010","unstructured":"Turcotte S, Sideris L, Younan R, et al. Pharmacokinetics of intraperitoneal irinotecan in a pig model. J Surg Oncol. 2010;101:637\u201342.","journal-title":"J Surg Oncol."},{"key":"18874_CR27","volume":"14","author":"VCJ van de Vlasakker","year":"2024","unstructured":"van de Vlasakker VCJ, Guchelaar NAD, van den Heuvel TBM, et al. Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases: protocol of the multicentre, open-label, phase II. INTERACT-II trial BMJ Open. 2024;14:e077667.","journal-title":"INTERACT-II trial. BMJ Open."},{"key":"18874_CR28","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1385\/MO:19:4:261","volume":"19","author":"H Ehrsson","year":"2002","unstructured":"Ehrsson H, Wallin I, Yachnin J. Pharmacokinetics of oxaliplatin in humans. Med Oncol. 2002;19:261\u20135.","journal-title":"Med Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18874-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18874-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18874-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:47:29Z","timestamp":1773330449000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18874-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,25]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["18874"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18874-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,25]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ignace De Hingh received research grants unrelated to the submitted work from QP&S, RanD Biotech, and Hoffman-La Roche. The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}